JNJ-Q2

JNJ-Q2
Clinical data
Routes of; administration	Oral, IV
Identifiers
	IUPAC name 7-[(3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid;
CAS Number	878592-87-1 ;
ChemSpider	9721013 ;
UNII	070SV15RJA;
CompTox Dashboard (EPA)	DTXSID20236667 ;
Chemical and physical data
Formula	C21H23F2N3O4
Molar mass	419.429 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1c(c(OC)c2c(c1)C(=O)C(\C(=O)O)=C/N2C3CC3)N4C/C(=C(/F)CN)CCC4;
	InChI InChI=InChI=1S/C21H23F2N3O4/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29)/b16-11+ ; Key:VMKVDAAFMQKZJS-LFIBNONCSA-N ;

JNJ-Q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically, JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.^[2]^[3]

Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica, a unit of Johnson & Johnson, which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed.^[4]

As of 2016, tests are ongoing.^[5]

References[edit]

^ "CSID:9721013". ChemSpider. Retrieved Aug 30, 2012.
^ Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN (July 2011). "JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains". Antimicrobial Agents and Chemotherapy. 55 (7): 3631–4. doi:10.1128/AAC.00162-11. PMC 3122438. PMID 21555765.
^ Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K (May 2010). "In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone". Antimicrobial Agents and Chemotherapy. 54 (5): 1955–64. doi:10.1128/AAC.01374-09. PMC 2863672. PMID 20176911.
^ "Novel Fluoroquinolone (JNJ-Q2)". Furiex Pharmaceuticals.
^ Jones TM, Johnson SW, DiMondi VP, Wilson DT (2016). "Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections". Infection and Drug Resistance. 9: 119–28. doi:10.2147/IDR.S105620. PMC 4908938. PMID 27354817.

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

[1] "CSID:9721013". ChemSpider. Retrieved Aug 30, 2012.

[2] Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN (July 2011). "JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains". Antimicrobial Agents and Chemotherapy. 55 (7): 3631–4. doi:10.1128/AAC.00162-11. PMC 3122438. PMID 21555765.

[3] Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K (May 2010). "In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone". Antimicrobial Agents and Chemotherapy. 54 (5): 1955–64. doi:10.1128/AAC.01374-09. PMC 2863672. PMID 20176911.

[4] "Novel Fluoroquinolone (JNJ-Q2)". Furiex Pharmaceuticals.

[5] Jones TM, Johnson SW, DiMondi VP, Wilson DT (2016). "Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections". Infection and Drug Resistance. 9: 119–28. doi:10.2147/IDR.S105620. PMC 4908938. PMID 27354817.

[1]

[2]

[3]

[4]

[5]